Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL)
| Autor: | Margreet Th.E. Bink-Boelkens, Judith M. Vonk, Cornelia Brouwer, Aleida Postma, Willem A. Kamps, Jourik A. Gietema, Jaap Haaksma, M.P. van den Berg, N. J. Elzenga |
|---|---|
| Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Cardiovascular Centre (CVC), Groningen Research Institute for Asthma and COPD (GRIAC) |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Cardiac function curve Adult Male medicine.medical_specialty Time Factors Adolescent Daunorubicin Antineoplastic Agents Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines Survivors Risk factor Child GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) Childhood Acute Lymphoblastic Leukemia Oncology(nursing) Cardiotoxicity Oncology (nursing) business.industry Cumulative dose Cancer Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Cross-Sectional Studies Anesthesia Child Preschool Heart Function Tests ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female Post treatment business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of cancer survivorship-Research and practice, 1(4), 255-260. SPRINGER |
| ISSN: | 1932-2259 |
| Popis: | In children with cancer a well-known risk factor for cardiotoxicity is a high cumulative dose of anthracyclines, but little is known about cardiac function in low-dose anthracycline-treated survivors. Also, it is unclear if a safe anthracycline-dose exists at all.Cardiac function was assessed in 23 long-term ALL-survivors with a median follow-up of 22 years (range 19.5-24.5) post-treatment. Age at diagnosis and current age were 5.0 (2.0-14.0) and 29.0 (24.0-39.0) years. All 23 survivors were treated according to DCLSG protocol ALL-5, including 18-25 Gy cranial irradiation. Thirteen of them received 4 x 25 mg/m(2) daunorubicin by randomization. Cardiac evaluation included blood pressure measurement, echocardiography, and (24 h-) electrocardiogram. Results were compared with an earlier assessment at median 12 years post-treatment.None of the survivors had cardiac abnormalities. Cardiac status of daunorubicin-treated survivors showed no deterioration compared with the previous assessment in 1995. CONCLUSION AND IMPLICATION FOR CANCER SURVIVORS: After prolonged follow-up (more than 20 years post-treatment), ALL-survivors treated with low dose daunorubicin had no clinical relevant deterioration of cardiac function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink